N-(3-ethylphenyl)propanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-ethylphenyl)propanamide
• 化学式: C₁₁H₁₅NO
• mdl: MFCD03366239
• 分子量: 177.24
• InChiKey: GRIYJAPYJIGCMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Calderwood Emily F.

  公开号：US20120015942A1

  公开（公告）日：2012-01-19

  This invention provides compounds of formula (I): wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 2c , and R 2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  这项发明提供了式（I）的化合物： 其中R1a、R1b、R1c、R2a、R2b、R2c和R2d的取值如规范中所述，可用作HDAC6的抑制剂。该发明还提供了包括该发明化合物的药物组合物，以及在治疗增殖性、炎症性、感染性、神经系统或心血管疾病或紊乱中使用这些组合物的方法。
• Process for the catalytic debromination of halogenated monocyclic aromatic compounds
  申请人：HOECHST CELANESE CORPORATION

  公开号：EP0593251A1

  公开（公告）日：1994-04-20

  A process for the bromination of a monocyclic aromatic compound and its regiospecific chlorination. The halogenation reactions are carried out in a protonic solvent which is replaced by a polar solvent without isolation of the halogenation reaction product. The halogenation reaction product is then catalytically debrominated.

  一种单环芳烃化合物的溴化和其区域特异性氯化的过程。卤化反应在质子溶剂中进行，该溶剂被极性溶剂取代，而无需分离卤化反应产物。然后对卤化反应产物进行催化去溴反应。
• ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3202766A1

  公开（公告）日：2017-08-09

  It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.

  研究发现，具有异噁唑骨架的通式（I）化合物对突变型 IDH1 蛋白具有极好的抑制活性，并能抑制该蛋白产生 2-HG，同时该化合物还能有效抑制表达该蛋白的各种肿瘤的生长。式中，R1、R2、R3、Y 和 Z 如权利要求 1 所定义。
• Heteroaryl compounds and uses thereof
  申请人：Celgene CAR LLC

  公开号：US10189794B2

  公开（公告）日：2019-01-29

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、其药学上可接受的组合物及其使用方法。
• Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
  申请人：PharmAkea, Inc.

  公开号：US11072585B2

  公开（公告）日：2021-07-27

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了作为 LOXL2 抑制剂的化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物，以及使用此类化合物治疗与 LOXL2 活性相关的病症、疾病或失调的方法。